Wall Street Falls as Fed Minutes Signal Another Rate Hike 
Asian Stocks Rise as Nasdaq Record Offsets Bond Yield Pressure 
Nasdaq Hits Record High as Tech Stocks Lift Wall Street 
Samsung, SK Hynix Shares Fall Ahead of Q3 Earnings 
Australia Consumer Confidence Plunges as RBA Rate Hike Hits Households 
HSBC Plans Deep UK Wealth Job Cuts in AI Push 
France to Release 10 Million Barrels of Diesel to Ease Fuel Prices 
Founders Fund Leads $5M Anvil Token Purchase 
Asian Currencies Steady as Dollar Holds Near 18-Month High 
RBI Raises Repo Rate to 5.50% in Hawkish Shift on Inflation Risks 
US Stock Futures Flat as Fed Minutes, Earnings Loom 
LG Electronics Shares Slide as Q3 Profit Misses Estimates 
Gate Launches Gate Money as Crypto Super App Race Heats Up 
Oil Prices Rise as Hormuz Attacks Fuel Supply Fears 
Kazakhstan and Tether Explore Tenge Stablecoin and RWA Tokenization 
Florida Seeks Tougher Meta Rules to Protect Young Users 
Robinhood Buys $25 Million in Bitcoin for Corporate Treasury 
Add as a preferred source on Google
South Korea’s Hanmi Pharm Co., Celltrion Inc., and Dongbang FTL were among 27 drugmakers chosen to produce low-cost versions of Merck & Co.’s COVID-19 pill molnupiravir for low- and-middle-income countries.
The Medicines Patent Pool (MPP), an UN-backed public health organization, announced that it signed sublicense agreements with 27 generic drug manufacturers to produce molnupiravir to be supplied to 105 countries.
Celltrion will manufacture the finished drug and Dongbang FTL will produce ingredients, while Hanmi will do both.
The MPP signed a licensing agreement with the US drugmaker last year to boost global access for molnupiravir.
The South Korean government would support its three pharmaceutical companies involved in the deal by easing regulations and establishing a consultative entity involving government ministries and companies.
According to MPP, which works to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries, the companies offered the sublicense have demonstrated their ability to meet its requirements for production capacity, regulatory compliance, and the ability to meet international standards for quality-assured medicines.
The MPP’s list of 27 generic manufacturers also includes 10 Indian and two Chinese firms.
Out of the 27 companies, 13 will produce both raw ingredients and the finished drug, according to the MPP.
